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Summary
There is currently particular interest in the field of nuclear
reprogramming, a process by which the identity of specialised
cells may be changed, typically to an embryonic-like state.
Reprogramming procedures provide insight into many
mechanisms of fundamental cell biology and have several
promising applications, most notably in healthcare through the
development of human disease models and patient-specific
tissue-replacement therapies. Here, we introduce the field of
nuclear reprogramming and briefly discuss six of the procedures
by which reprogramming may be experimentally performed:
nuclear transfer to eggs or oocytes, cell fusion, extract treatment,
direct reprogramming to pluripotency and transdifferentiation.
Key words: Transdifferentiation, Cell fusion, Induced pluripotency,
Nuclear transfer, Pluripotent, Reprogramming
Introduction
The differentiated state of somatic cells is considered to be highly
stable. During embryogenesis, developmentally plastic stem cells
become specified, committed and ultimately restricted to particular
cellular lineages in a highly coordinated manner. Once
differentiated, somatic cells very rarely change from one
differentiation state to another. When this does occur, however, it is
often associated with disease and particularly cancer formation. The
differentiated state of a somatic cell may be reversed experimentally
to that of another cell type by a process termed ‘nuclear
reprogramming’ (Gurdon and Melton, 2008). Nuclear
reprogramming can most simply be defined as ‘a process by which
the differentiation state of a cell is changed to that of another state’.
This may involve a differentiated cell reverting to a state of
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increased developmental plasticity (‘de-differentiation’), or a switch
from one differentiated cell type to another (‘transdifferentiation’
or ‘direct reprogramming’). In its most extreme form, terminally
differentiated cells may be reprogrammed to a state of totipotency,
so that they are then capable of developing into a new adult animal.
The identity of any cell is determined by the expression of the
lineage-specific genes that confer cellular identity (cellular
phenotype). Consequently, in order to change a particular identity,
a cell has to turn on new lineage-specific genes and turn off the old
ones. As such, changes in transcription patterns are core to
successful reprogramming, as is also the case with normal
development. Reprogramming of somatic cells therefore involves
resetting the epigenetic mechanisms that maintain stable gene
expression, such as DNA methylation and histone modifications
(Pasque et al., 2011). As well as these changes in gene expression
profiles, successful nuclear reprogramming involves many other
fundamental changes in cellular function, such as DNA replication,
nuclear organisation, cell division and metabolism. The
experimental induction of reprogramming gives researchers a
window to understand these fundamental aspects of cell biology.
In addition to using reprogramming technologies as a tool to
understand fundamental biology, the reprogramming of somatic
cells carries significant potential medical value. Recent advances in
the reprogramming field have led to the development of a number
of human disease models, generated from the reprogramming of
diseased somatic cells (Wu and Hochedlinger, 2011; Yamanaka,
2012). These will undoubtedly be invaluable in understanding and
combating a number of human diseases. The use of reprogrammed
human cells also provides an ethically attractive source of
autologous human tissue for cell replacement therapies (Wu and
Hochedlinger, 2011).
This article will highlight the range of techniques by which
nuclear reprogramming may be studied by experimental induction
in the laboratory.
Nuclear reprogramming by nuclear transfer to
eggs (meiotic metaphase II oocytes)
Nuclear transfer involves the physical transplantation of a single
nucleus into a meiotic metaphase II arrested egg (or ‘MII oocyte’ in
the mammalian field), usually after removing the recipient egg’s
genetic material. It was by this method that the first cloning of
amphibians and later of mammals was performed (Gurdon et al.,
1958; Wakayama et al., 1998; Wilmut et al., 1997) and is often
called ‘somatic cell nuclear transfer’ (SCNT). This procedure was
initially used to establish the concept of genome conservation during
development (Briggs and King, 1952; Gurdon et al., 1958). These
early experiments also demonstrated that the cloning of an animal
was possible. Nuclear transfer has been successfully used to
reprogramme many different species (Byrne et al., 2007; Cibelli,
2007; Noggle et al., 2011; Wakayama and Yanagimachi, 1999) and
much of our understanding of reprogramming comes from
experiments using this system (reviewed by Gurdon and Wilmut,
2011). The cloned embryonic cells resulting from the procedure
may also be harvested and cultured in vitro. By this means, it is
possible to derive embryonic stem cells (ESCs) from cloned
mammalian embryos (Byrne et al., 2007; Noggle et al., 2011; Yang
et al., 2007). Such cultured embryonic cells may also be
differentiated into various adult cell types (Wakayama et al., 2001).
Nuclear reprogramming by this route is thought to ‘mimic’
natural fertilisation; the oocyte attempts to reprogramme the
incoming somatic nucleus in much the same way as it
reprogrammes the paternal genome after fertilisation (Gao et al.,
2007). Reprogramming by SCNT is mediated by natural
components of the egg and involves extensive DNA replication and
cell division (Jullien et al., 2011). This constantly changing nuclear
landscape and the practical limitations of SCNT makes studying the
early transcriptional changes involved in reprogramming somewhat
difficult (Jullien et al., 2011).
The efficiency of SCNT, as judged by the generation of entirely
normal adult animals, is low, below ~1-2% when adult somatic
nuclei are used as donors (Yang et al., 2007). Additionally, some
clones may display a number of abnormalities, phenotypically and
at a molecular and physiological level (Wilmut et al., 2002; Yang et
al., 2007). The low efficiency and abnormalities are likely to be
attributable to a failure to completely reprogramme the donor
genome, reflecting the ‘stability of differentiation’ seen in adult
cells. This is illustrated by the phenomenon of ‘epigenetic memory’,
in which a ‘memory’ of the donor cell gene expression is retained
by some cells of the resulting cloned embryos. This has been shown
to be in part due to incomplete resetting of epigenetic factors, such
as DNA methylation and histone variants, in the donor nucleus (Ng
and Gurdon, 2007).
Direct transcriptional reprogramming by nuclear
transfer to prophase I amphibian oocytes
A modified form of SCNT involves transplanting multiple somatic
nuclei into the enlarged nucleus [termed the germinal vesicle (GV)]
of developing amphibian oocytes. These large immature oocytes
are arrested in meiotic prophase I and are undergoing intense
production of the maternal transcripts and proteins that will be
necessary for supporting early embryonic development until zygotic
genome activation (Gao et al., 2002).
There is no DNA replication or cell division by this
reprogramming route and, as such, no new cell types are generated.
There is, however, considerable transcriptional reactivation of
certain silent genes within a few hours (Halley-Stott et al., 2010). By
this procedure, silent genes [such as the pluripotency genes Oct4
(Pou5f1) and Sox2] in the somatic donor nuclei become directly
activated, in the absence of cell division and protein synthesis
(Halley-Stott et al., 2010). The oocyte will transcriptionally
reprogramme nuclei from another species (mouse, for example),
allowing newly synthesised transcript to be distinguished from the
maternal content of the oocyte by sequence identity.
Using this system, it is possible to explore the conditions that are
required to promote the activation of silent genes, a process that
may be referred to as ‘transcriptional reprogramming’. The large
size of the Xenopus oocyte and the ease of manipulating endogenous
reprogramming factors by overexpression or knockdown make this
system a powerful tool for studying reprogramming in a purely
transcriptional context.
Reprogramming by cell fusion
Transcriptional changes in somatic cells can be achieved by fusing
the plasma membranes of different cell types. The use of embryonic
‘dominant’ cells, such as ESCs, to reprogramme somatic cells can
induce the transcription of pluripotency-associated genes under the
correct conditions (Yamanaka and Blau, 2010). Upon fusion, the
nuclei of both cell types can remain separate in the common
cytoplasm (heterokaryon formation) or, after mitosis, fuse
themselves to form a hybrid genome (synkaryon). In the case of
early heterokaryons, there is thought to be no cell division and a
direct transactivation of genes in the responding cell (Chiu and Blau,
1984), although the role of DNA synthesis during heterokaryon-











contrast, synkaryons undergo DNA replication and cell division,
forming a hybrid genome with a mixture of genetic material from
both starting nuclei, although often chromosomes from one of the
genomes are lost (Yamanaka and Blau, 2010).
As in the case of nuclear reprogramming with GV-stage oocytes,
heterokaryon reprogramming may also be performed within or
across species (Yamanaka and Blau, 2010). The latter case permits
researchers to easily follow transcriptional changes in the
responding nucleus without contributing signals from ‘carry-over’
transcript derived from the dominant cell. Moreover, the ability to
manipulate both the responding and dominant cells using standard
cell culture techniques makes cell fusion a useful technique for
studying the mechanisms that underpin the early stages of
reprogramming (Piccolo et al., 2011).
Reprogramming by extract treatment
Reprogramming may also be achieved, at least in part, by exposing
permeabilised cells to protein extracts that are prepared, for
example, from pluripotent cells (Taranger et al., 2005). The plasma
membranes of these permeabilised cells may then be re-sealed and
the cells cultured, leading to the expression of previously silent
genes. This reprogramming is thought to be associated with cell
division and DNA replication in most instances. As with the other
reprogramming procedures, the efficiency of extract-based
reprogramming appears to be low (Bru et al., 2008).
Extract treatment as a reprogramming system is relatively less
developed than other systems. However, an appealing aspect of
reprogramming by this means is the ability to biochemically
introduce or deplete reprogramming factors to or from the extract.
Furthermore, the use of extract provides an opportunity for
biochemical fractionation, potentially allowing investigators to
identify novel reprogramming factors (Singhal et al., 2010). Extract-
treated cells may also be subsequently used as starting material for
induced pluripotency or SCNT experiments (Bui et al., 2012; Ganier
et al., 2011). Extracts prepared from relatively differentiated cells
may also be used to ‘transdifferentiate’ cells, at least in part
(Håkelien et al., 2002). Reproducibility of extract treatments is a
concern in the field (Liu et al., 2011; Singhal et al., 2010). This is
probably due to the difficulty of preparing high quality extracts,
which might be solved as this system develops.
Reprogramming by transcription factor
overexpression (induced pluripotency)
The most recent major advance in reprogramming was the
discovery that cells could be reprogrammed by the overexpression
of key transcription factors (Takahashi and Yamanaka, 2006). Four
transcription factors (Oct4, Sox2, Klf4 and Myc) can be virally
transfected into somatic cells and, under the correct cell culture
conditions, will reprogramme some of them to an ESC-like state,
generating what are termed ‘induced pluripotent stem cells’ (iPSCs)
(Yamanaka, 2012).
Reprogramming by this route drives the induction of pluripotent
gene expression profiles reminiscent of ESCs, while largely
silencing somatic gene expression. There is extensive DNA
replication and cell division leading to the generation of cells of this
new identity (Koche et al., 2011). These cells may then be
differentiated into any cell type of the adult body (Takahashi and
Yamanaka, 2006).
Research on iPSCs has exploded in the last 5 years with a number
of technological advancements and mechanistic insights coming to
the fore (Papp and Plath, 2013). A significant portion of the work
has focused on enhancing the low efficiency of induced
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pluripotency-based reprogramming, which is thought result at least
partially from the repressive nature of chromatin at repressed loci in
somatic cells and the stochastic nature of the procedure (Hanna et
al., 2009; Jullien et al., 2011; Papp and Plath, 2013).
In addition, a large amount of research has been directed at
generating iPSCs without the use of the oncogene Myc and viral
gene delivery vehicles, in order to eliminate potential oncogenesis
(Nakagawa et al., 2008; Yamanaka, 2012). The primary drive
behind this work is to develop systems to generate iPSCs in
sufficient numbers so that they may be safely used for tissue
replacement therapies (Okita and Yamanaka, 2011).
As with other reprogramming systems, there also appears to be a
degree of epigenetic memory in iPSCs, with reprogrammed cells
displaying epigenetic signatures related to the original cell type from
which they were reprogrammed (Graf, 2009). Efforts are being
made to overcome this and there is no reason why this should limit
the medical application of this technology in the future.
Transdifferentiation by transcription factor
overexpression (direct programming)
An exciting recent branch of reprogramming encompasses
‘transdifferentiation’ or ‘transversion’, whereby a somatic cell is
switched from one identity to another, but not necessarily to one of
increased developmental plasticity. The use of a cocktail of
transcription factors has been successfully used to transdifferentiate
a number of cell types from one lineage to that of another (Graf,
2011; Vierbuchen and Wernig, 2012).
Such reprogramming may occur within a lineage, such as the
conversion of an exocrine cell to an endocrine cell (both endoderm
derived) (Zhou et al., 2008) or alternatively across lineages, as has
been demonstrated by the conversion of fibroblasts to neurons
(mesoderm-to-ectoderm lineage switch) (Vierbuchen et al., 2010).
It can be expected that the list of cell types that can be subject to
transdifferentiation will continue grow as new combinations of
transcription factors, able to confer distinct cellular identities, are
identified (Vierbuchen and Wernig, 2011).
Transdifferentiation also promises a number of potential
advantages for the generation of clinically relevant cells, particularly
with respect to the efficiency of conversion, which appears to be
high in some cases. Additionally, cells derived by this route may
carry less risk of generating carcinomas because oncogenes need
not be used in the reprogramming procedure (Sancho-Martinez et
al., 2012).
Perspectives
Over the past six decades, nuclear reprogramming has acquired
ever-increasing momentum, fuelled by the realisation that it could
help to alleviate human suffering as well as uncover fundamental
biological principles.
Despite the many major advances in the reprogramming field
made in recent years, there are still a number of challenges facing
investigators. Key outstanding questions include: What are the
molecular mechanisms of nuclear reprogramming? Why is the
efficiency of the process so low? What factors and mechanisms
maintain the stable state of cellular identity? In each system, what
are the steps of nuclear reprogramming? Does reprogramming by
induced pluripotency or transdifferentiation involve a gradual
reversion of the developmental steps followed during
embryogenesis? What can we learn about the mechanisms of
diseases using reprogrammed cells from patients? And most
importantly, can we design effective new cures starting from a
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cells? Progress so far and the development of modern laboratory
techniques provide a battery of invaluable tools to address these
outstanding questions and the field can expect many more exciting
fundamental and applied discoveries in the coming decades.
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